PortalPublikationenAssessment of the range of the HIV-1 infectivity enhancing e...

Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.

Standard

Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG. / Hartjen, Philip; Frerk, Sebastian; Hauber, Ilona; Matzat, Verena; Thomssen, Adriana; Holstermann, Barbara; Hohenberg, Heinrich; Schulze, Wolfgang; Schulze Zur Wiesch, Julian; van Lunzen, Jan.

in: AIDS RES THER, Jahrgang 9, Nr. 1, 1, 2012, S. 2.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hartjen, P, Frerk, S, Hauber, I, Matzat, V, Thomssen, A, Holstermann, B, Hohenberg, H, Schulze, W, Schulze Zur Wiesch, J & van Lunzen, J 2012, 'Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.', AIDS RES THER, Jg. 9, Nr. 1, 1, S. 2. https://doi.org/10.1186/1742-6405-9-2

APA

Hartjen, P., Frerk, S., Hauber, I., Matzat, V., Thomssen, A., Holstermann, B., Hohenberg, H., Schulze, W., Schulze Zur Wiesch, J., & van Lunzen, J. (2012). Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG. AIDS RES THER, 9(1), 2. [1]. https://doi.org/10.1186/1742-6405-9-2

Vancouver

Hartjen P, Frerk S, Hauber I, Matzat V, Thomssen A, Holstermann B et al. Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG. AIDS RES THER. 2012;9(1):2. 1. https://doi.org/10.1186/1742-6405-9-2

Bibtex

@article{59c6c81246ec417792e669f4ef59de90,
title = "Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.",
abstract = "Recently, it has been shown that human ejaculate enhances human immunodeficiency virus 1 (HIV-1) infectivity. Enhancement of infectivity is conceived to be mediated by amyloid filaments from peptides that are proteolytically released from prostatic acid phosphatase (PAP), termed Semen-derived Enhancer of Virus Infection (SEVI). The aim of this study was to test the range of HIV-1 infectivity enhancing properties of a large number of individual semen samples (n = 47) in a TZM-bl reporter cell HIV infection system. We find that semen overall increased infectivity to 156% of the control experiment without semen, albeit with great inter- and intraindividual variability (range -53%-363%). Using transmission electron microscopy, we provide evidence for SEVI fibrils in fresh human semen for the first time. Moreover, we confirm that the infectivity enhancing property can be inhibited by the major green tea ingredient epigallocatechin-3-gallate (EGCG) at non-toxic concentrations. The median inhibition of infection by treatment with 0.4 mM EGCG was 70.6% (p <0.0001) in our cohort. Yet, there were substantial variations of inhibition and in a minority of samples, infectivity enhancement was not inhibited by EGCG treatment at all. Thus, topical application of EGCG may be a feasible additional measure to prevent the sexual transmission of HIV. However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted.",
author = "Philip Hartjen and Sebastian Frerk and Ilona Hauber and Verena Matzat and Adriana Thomssen and Barbara Holstermann and Heinrich Hohenberg and Wolfgang Schulze and {Schulze Zur Wiesch}, Julian and {van Lunzen}, Jan",
year = "2012",
doi = "10.1186/1742-6405-9-2",
language = "English",
volume = "9",
pages = "2",
journal = "AIDS RES THER",
issn = "1742-6405",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.

AU - Hartjen, Philip

AU - Frerk, Sebastian

AU - Hauber, Ilona

AU - Matzat, Verena

AU - Thomssen, Adriana

AU - Holstermann, Barbara

AU - Hohenberg, Heinrich

AU - Schulze, Wolfgang

AU - Schulze Zur Wiesch, Julian

AU - van Lunzen, Jan

PY - 2012

Y1 - 2012

N2 - Recently, it has been shown that human ejaculate enhances human immunodeficiency virus 1 (HIV-1) infectivity. Enhancement of infectivity is conceived to be mediated by amyloid filaments from peptides that are proteolytically released from prostatic acid phosphatase (PAP), termed Semen-derived Enhancer of Virus Infection (SEVI). The aim of this study was to test the range of HIV-1 infectivity enhancing properties of a large number of individual semen samples (n = 47) in a TZM-bl reporter cell HIV infection system. We find that semen overall increased infectivity to 156% of the control experiment without semen, albeit with great inter- and intraindividual variability (range -53%-363%). Using transmission electron microscopy, we provide evidence for SEVI fibrils in fresh human semen for the first time. Moreover, we confirm that the infectivity enhancing property can be inhibited by the major green tea ingredient epigallocatechin-3-gallate (EGCG) at non-toxic concentrations. The median inhibition of infection by treatment with 0.4 mM EGCG was 70.6% (p <0.0001) in our cohort. Yet, there were substantial variations of inhibition and in a minority of samples, infectivity enhancement was not inhibited by EGCG treatment at all. Thus, topical application of EGCG may be a feasible additional measure to prevent the sexual transmission of HIV. However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted.

AB - Recently, it has been shown that human ejaculate enhances human immunodeficiency virus 1 (HIV-1) infectivity. Enhancement of infectivity is conceived to be mediated by amyloid filaments from peptides that are proteolytically released from prostatic acid phosphatase (PAP), termed Semen-derived Enhancer of Virus Infection (SEVI). The aim of this study was to test the range of HIV-1 infectivity enhancing properties of a large number of individual semen samples (n = 47) in a TZM-bl reporter cell HIV infection system. We find that semen overall increased infectivity to 156% of the control experiment without semen, albeit with great inter- and intraindividual variability (range -53%-363%). Using transmission electron microscopy, we provide evidence for SEVI fibrils in fresh human semen for the first time. Moreover, we confirm that the infectivity enhancing property can be inhibited by the major green tea ingredient epigallocatechin-3-gallate (EGCG) at non-toxic concentrations. The median inhibition of infection by treatment with 0.4 mM EGCG was 70.6% (p <0.0001) in our cohort. Yet, there were substantial variations of inhibition and in a minority of samples, infectivity enhancement was not inhibited by EGCG treatment at all. Thus, topical application of EGCG may be a feasible additional measure to prevent the sexual transmission of HIV. However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted.

U2 - 10.1186/1742-6405-9-2

DO - 10.1186/1742-6405-9-2

M3 - SCORING: Journal article

VL - 9

SP - 2

JO - AIDS RES THER

JF - AIDS RES THER

SN - 1742-6405

IS - 1

M1 - 1

ER -